MSCs and osteoarthritis: reading the trial data.

Osteoarthritis of the knee is the single condition where MSC therapy has the largest body of published trial data. The reason is structural: the knee is accessible, the pathology is local, the outcome measures are well established, and the patient population is enormous. As a result the literature has matured to a point where we can talk honestly about effect sizes, durability, and what the protocol actually does.

What the trials measure

Most contemporary knee-OA trials use the WOMAC index, three subscales covering pain, stiffness and function, supplemented by visual analogue pain scales, range of motion, and imaging endpoints. Imaging in OA is notoriously hard to move; MRI changes in cartilage thickness across six to twelve months are subtle. The trials that have been most informative measure WOMAC at three, six and twelve months, with imaging at twelve months as a secondary endpoint.

The signal

The convergent picture across the published RCTs and meta-analyses is a clinically meaningful improvement in pain and function compared to saline or hyaluronic-acid controls, with effect sizes that are modest but durable through six to twelve months. The improvement is real. It is not a cure for the joint. It is a shift in symptom trajectory that often allows patients to delay or defer a planned arthroplasty.

The imaging picture is more equivocal. Some trials show slowed progression of cartilage loss; some do not. The mechanistic explanation we find most coherent, and consistent with the broader MSC mechanism literature, is that the dominant effect is immunomodulation of the synovial environment rather than structural regeneration of cartilage. That matters for managing patient expectations.

Where the practice diverges from the trials

The trials, on average, use a single intra-articular injection of a defined cell dose. Our stem-cell technology protocol for OA, supervised by our orthopaedic consultant Dr. Jakkarin Phunphakchit, is structured as a two-injection cycle eight to twelve weeks apart, with an intravenous component for clients whose inflammatory load reads systemically. The rationale is the same observation that runs through all of our MSC work: a single dose moves things; a structured cadence holds the gains.

We also pay close attention to the work upstream of the joint. A patient who arrives with knee OA, who is forty kilos over a healthy weight, with no strength training in their week, will get the modest signal the literature describes, and then lose it as the underlying load returns. Patients whose body composition, training pattern and inflammatory panel are addressed in parallel to the intra-articular protocol tend to hold the gains substantially longer.

Who responds and who doesn't

Kellgren-Lawrence grade is the single most consistent predictor of response. Patients with grade 2 to early grade 3 disease respond meaningfully. Patients with grade 4 disease and substantial structural loss respond modestly at best, and the honest conversation is usually about delaying arthroplasty by twelve to twenty-four months rather than avoiding it.

Age and BMI matter. Inflammatory load matters. The integrity of the meniscus matters. Whether the patient has had prior corticosteroid injections matters, because repeated cortisone has known cartilage costs and may bias the response window. We review every OA case with imaging, the inflammatory panel, and an orthopaedic read before agreeing on a protocol.

The honest framing

MSC therapy for knee OA is, in our reading, the most evidence-defensible application of regenerative medicine in current clinical practice. The signal is real, the safety profile is benign across the trials, and the patient experience is straightforward. It is also not a cure for an arthritic joint, and the most rewarding protocols are the ones run alongside the orthopaedic disciplines, gait, strength, weight, mobility, that determine whether the joint holds the gains.

The next read for orthopaedic clients is what we know about MSC therapy for stroke recovery, different organ, similar mechanism, useful for understanding what immunomodulation actually does in the body.